Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDUARDO WEISS

Allopathic & Osteopathic Physicians Dermatology

NPI
1053308965
CMS profile
2793
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$103,804.75

182 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDUARDO WEISS

NPI 1053308965 · CMS profile ID 2793

Allopathic & Osteopathic Physicians / Dermatology

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053308965?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDUARDO WEISS, NPI 1053308965, CMS profile ID 2793. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053308965?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). EDUARDO WEISS, NPI 1053308965, CMS profile ID 2793. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053308965?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
EDUARDO WEISS, NPI 1053308965, CMS profile ID 2793, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1053308965?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

182 matching records · $103,804.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 182 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–182 of 182.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $24.0903/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892627959 CMS
Janssen Biotech, Inc. $27.2103/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885672207 CMS
Sun Pharmaceutical Industries Inc. $139.9502/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947765293 CMS
Regeneron Healthcare Solutions, Inc. $5.5902/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927469543 CMS
Regeneron Healthcare Solutions, Inc. $1.8302/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927469549 CMS
Lilly USA, LLC $25.6202/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918066093 CMS
ABBVIE INC. $4.7702/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892627953 CMS
ABBVIE INC. $3,125.0002/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892627955 CMS
ABBVIE INC. $26.0002/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892627957 CMS
PFIZER INC. $20.7302/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949118231 CMS
ABBVIE INC. $123.5302/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892627951 CMS
Janssen Biotech, Inc. $31.2002/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885672225 CMS
Janssen Biotech, Inc. $19.7402/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885672149 CMS
Allergan, Inc. $4,550.0002/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890005563 CMS
Regeneron Healthcare Solutions, Inc. $15.5202/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927469537 CMS
ABBVIE INC. $5.0202/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892627949 CMS
Novartis Pharmaceuticals Corporation $19.4902/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894446547 CMS
Allergan, Inc. $4,550.0001/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890005561 CMS
Janssen Biotech, Inc. $18.2801/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885672189 CMS
EPI Health, LLC $2.9801/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960437433 CMS
LEO Pharma Inc. $19.5801/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936302673 CMS
Allergan, Inc. $4,550.0001/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890005559 CMS
Lilly USA, LLC $25.9801/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918008837 CMS
Allergan, Inc. $1,950.0001/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890005557 CMS
ABBVIE INC. $21.6801/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892627947 CMS
Allergan, Inc. $4,550.0001/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890005555 CMS
EPI Health, LLC $23.7601/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960437431 CMS
ABBVIE INC. $21.0001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892627945 CMS
Allergan, Inc. $4,550.0001/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890005553 CMS
GENZYME CORPORATION $21.3201/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938856853 CMS
Allergan, Inc. $4,550.0001/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890005549 CMS
Allergan, Inc. $23.4901/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890005551 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $65,843.12 154
PY2020 $35,539.20 136
PY2021 $85,819.28 193
PY2022 $103,804.75 182
PY2023 $43,545.24 169
PY2024 $30,273.67 191
PY2025 $19,509.65 171

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,099,342.79 594
PY2024 Recipient $104.58 1
PY2024 Principal investigator $1,073,446.45 743
PY2023 Principal investigator $729,924.19 415
PY2022 Recipient $944.00 1
PY2022 Principal investigator $595,300.50 78
PY2021 Recipient $839.52 1
PY2021 Principal investigator $868,543.94 73
PY2020 Recipient $293.47 1
PY2020 Principal investigator $383,597.48 59
PY2019 Recipient $5,000.00 1
PY2019 Principal investigator $324,257.25 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

594 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533091
Principal investigator 1 ABBVIE INC. $665.04 12/31/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis No dispute reported 06/30/2026 1202533271
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202533273
Principal investigator 1 PFIZER INC. $1,050.72 12/31/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228804244
Principal investigator 1 ABBVIE INC. $355.11 12/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202532174
Principal investigator 1 ABBVIE INC. $268.99 12/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202532176
Principal investigator 1 ABBVIE INC. $222.63 12/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202532188
Principal investigator 1 Incyte Corporation $264.00 12/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590097
Principal investigator 1 Incyte Corporation $1,784.00 12/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590132
Principal investigator 1 Incyte Corporation $270.00 12/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590175
Principal investigator 1 Incyte Corporation $225.00 12/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590185
Principal investigator 1 ABBVIE INC. $784.00 12/16/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202530586
Principal investigator 1 ABBVIE INC. $824.00 12/16/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202530594
Principal investigator 1 ABBVIE INC. $704.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202530086
Principal investigator 1 ABBVIE INC. $60.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202530088
Principal investigator 1 Incyte Corporation $76.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590067
Principal investigator 1 Incyte Corporation $9,930.60 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590075
Principal investigator 1 Incyte Corporation $229.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590080
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 12/09/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434467
Principal investigator 1 Incyte Corporation $5,147.20 12/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590214
Principal investigator 1 ABBVIE INC. $41,069.93 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527346
Principal investigator 1 ABBVIE INC. $6,432.60 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527348
Principal investigator 1 ABBVIE INC. $6,583.05 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202527440
Principal investigator 1 ABBVIE INC. $4,693.00 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527682
Principal investigator 1 Incyte Corporation $420.70 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590085
Principal investigator 1 Incyte Corporation $5,359.80 12/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590071
Principal investigator 1 ABBVIE INC. $5,000.00 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202526182
Principal investigator 1 Incyte Corporation $1,944.00 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590089
Principal investigator 1 Incyte Corporation $3.18 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590093
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590110
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590113
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590117
Principal investigator 1 Incyte Corporation $43.56 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590121
Principal investigator 1 Incyte Corporation $1.70 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590128
Principal investigator 1 Incyte Corporation $131.56 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590136
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590140
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590144
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590152
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590156
Principal investigator 1 Incyte Corporation $300.00 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590160
Principal investigator 1 Incyte Corporation $123.40 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590163
Principal investigator 1 Incyte Corporation $34.35 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590167
Principal investigator 1 Incyte Corporation $88.00 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590178
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590189
Principal investigator 1 Incyte Corporation $870.00 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590193
Principal investigator 1 Incyte Corporation $48.54 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590198
Principal investigator 1 Incyte Corporation $21.33 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590207
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590222
Principal investigator 1 Incyte Corporation $118.50 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590226
Principal investigator 1 Incyte Corporation $118.50 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590230
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590232
Principal investigator 1 Incyte Corporation $1,977.00 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590235
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590240
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590244
Principal investigator 1 ABBVIE INC. $1,430.63 11/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202525680
Principal investigator 1 Incyte Corporation $65.00 11/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590042
Principal investigator 1 Incyte Corporation $134.00 11/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590063
Principal investigator 1 Incyte Corporation $1,249.20 11/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590218
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $22,300.00 11/24/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797092
Principal investigator 1 ABBVIE INC. $259.44 11/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202524776
Principal investigator 1 ABBVIE INC. $5,158.00 11/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202525008
Principal investigator 1 ABBVIE INC. $1,006.87 11/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202525018
Principal investigator 1 Incyte Corporation $1,000.00 11/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590034
Principal investigator 1 Incyte Corporation $2,500.00 11/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590059
Principal investigator 1 ABBVIE INC. $207.90 11/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202524467
Principal investigator 1 ABBVIE INC. $300.00 11/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202524031
Principal investigator 1 Incyte Corporation $104.00 11/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590038
Principal investigator 1 Incyte Corporation $500.00 11/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590046
Principal investigator 1 Incyte Corporation $126.00 11/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590050
Principal investigator 1 Incyte Corporation $835.00 11/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590053
Principal investigator 1 Incyte Corporation $2,665.00 11/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590056
Principal investigator 1 ABBVIE INC. $17,852.35 11/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522891
Principal investigator 1 ABBVIE INC. $2,119.30 11/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202522951
Principal investigator 1 ABBVIE INC. $4,849.25 11/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522953
Principal investigator 1 ABBVIE INC. $4,136.40 11/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202521143
Principal investigator 1 ABBVIE INC. $4,174.27 11/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202521145
Principal investigator 1 PFIZER INC. $365.85 11/04/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228817328
Principal investigator 1 Incyte Corporation $124.54 11/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590105
Principal investigator 1 Incyte Corporation $137.40 11/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590125
Principal investigator 1 Incyte Corporation $270.80 11/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590171
Principal investigator 1 Incyte Corporation $1,842.30 10/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590020
Principal investigator 1 ABBVIE INC. $2,491.00 10/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202518737
Principal investigator 1 ABBVIE INC. $87.12 10/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202518739
Principal investigator 1 ABBVIE INC. $227.70 10/23/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202518259
Principal investigator 1 Incyte Corporation $2,714.40 10/23/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590031
Principal investigator 1 ABBVIE INC. $261.56 10/21/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202517481
Principal investigator 1 ABBVIE INC. $261.56 10/21/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202517497
Principal investigator 1 PFIZER INC. $2,891.63 10/21/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228823725
Principal investigator 1 PFIZER INC. $1,050.72 10/21/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228824255
Principal investigator 1 Incyte Corporation $1,920.60 10/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590203
Principal investigator 1 ABBVIE INC. $3,940.00 10/16/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517145
Principal investigator 1 Eli Lilly and Company $2,556.00 10/14/2025 Non-covered Recipient Entity
INTERNATIONAL DERMATOLOGY RESEARCH
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187883868
Principal investigator 1 Incyte Corporation $132.00 10/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590100
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,479.95 10/10/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434463
Principal investigator 1 ABBVIE INC. $5,313.60 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202513967
Principal investigator 1 ABBVIE INC. $6,755.04 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202513969
Principal investigator 1 ABBVIE INC. $5,834.57 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202514129
Principal investigator 1 ABBVIE INC. $370.93 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514131
Principal investigator 1 ABBVIE INC. $11,151.00 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202514291
Principal investigator 1 ABBVIE INC. $17,176.69 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514293
Principal investigator 1 ABBVIE INC. $7,929.72 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202514457
Principal investigator 1 Incyte Corporation $521.00 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590016
Principal investigator 1 Incyte Corporation $104.00 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590024
Principal investigator 1 Incyte Corporation $265.00 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240590027
Principal investigator 1 Incyte Corporation $2,013.30 10/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590182
Principal investigator 1 Novartis Pharmaceuticals Corporation $526.62 10/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190311105
Principal investigator 1 ABBVIE INC. $2,472.00 10/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202513059
Principal investigator 1 Incyte Corporation $1,035.80 10/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590148
Principal investigator 1 Incyte Corporation $2,134.00 10/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590211
Principal investigator 1 Janssen Research & Development, LLC $406.00 10/02/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187076
Principal investigator 1 ABBVIE INC. $2,352.00 09/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202512502
Principal investigator 1 ABBVIE INC. $8,183.00 09/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202512092
Principal investigator 1 Incyte Corporation $1,853.10 09/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589874
Principal investigator 1 ABBVIE INC. $3.64 09/16/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202511030
Principal investigator 1 Incyte Corporation $290.00 09/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589949
Principal investigator 1 Incyte Corporation $98.74 09/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589986
Principal investigator 1 ABBVIE INC. $3,912.92 09/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509312
Principal investigator 1 ABBVIE INC. $11,913.37 09/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202509314
Principal investigator 1 ABBVIE INC. $44,042.40 09/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509572
Principal investigator 1 ABBVIE INC. $13,813.00 09/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202507659
Principal investigator 1 ABBVIE INC. $1,805.70 09/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202507885
Principal investigator 1 Incyte Corporation $21.88 09/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589938
Principal investigator 1 Incyte Corporation $25.95 09/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589945
Principal investigator 1 ABBVIE INC. $723.12 09/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202506945
Principal investigator 1 PFIZER INC. $97.00 08/30/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228842480
Principal investigator 1 ABBVIE INC. $100.00 08/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202505807
Principal investigator 1 ABBVIE INC. $492.36 08/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202505847
Principal investigator 1 Incyte Corporation $467.00 08/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589886
Principal investigator 1 Incyte Corporation $88.00 08/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589896
Principal investigator 1 Incyte Corporation $90.00 08/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589900
Principal investigator 1 Incyte Corporation $65.00 08/21/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589857
Principal investigator 1 Incyte Corporation $1,760.90 08/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589883
Principal investigator 1 Incyte Corporation $1,388.00 08/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589917
Principal investigator 1 Incyte Corporation $1,388.00 08/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590013
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $405.00 08/20/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434459
Principal investigator 1 ABBVIE INC. $1,144.02 08/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202504797
Principal investigator 1 Incyte Corporation $602.80 08/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589868
Principal investigator 1 Incyte Corporation $2,191.50 08/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589871
Principal investigator 1 ABBVIE INC. $191.10 08/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202504123
Principal investigator 1 Incyte Corporation $70.83 08/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589904
Principal investigator 1 Incyte Corporation $66.00 08/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589961
Principal investigator 1 Incyte Corporation $58.00 08/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589965
Principal investigator 1 Incyte Corporation $707.52 08/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589970
Principal investigator 1 Incyte Corporation $126.00 08/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589973
Principal investigator 1 Incyte Corporation $158.00 08/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590003
Principal investigator 1 ABBVIE INC. $74.18 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202503877
Principal investigator 1 ABBVIE INC. $27.82 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202503917
Principal investigator 1 ABBVIE INC. $18.55 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202503943
Principal investigator 1 Eli Lilly and Company $100.00 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187889998
Principal investigator 1 Incyte Corporation $470.70 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589861
Principal investigator 1 Incyte Corporation $650.00 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589865
Principal investigator 1 ABBVIE INC. $471.15 08/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202502983
Principal investigator 1 ABBVIE INC. $12,489.48 08/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502985
Principal investigator 1 ABBVIE INC. $317.52 08/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503115
Principal investigator 1 ABBVIE INC. $52,304.39 08/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503117
Principal investigator 1 ABBVIE INC. $1,415.55 08/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202503213
Principal investigator 1 ABBVIE INC. $1,674.84 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501582
Principal investigator 1 ABBVIE INC. $130.38 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202501714
Principal investigator 1 ABBVIE INC. $66.65 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202501716
Principal investigator 1 ABBVIE INC. $2,538.00 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501794
Principal investigator 1 ABBVIE INC. $396.67 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202501886
Principal investigator 1 ABBVIE INC. $62.82 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501888
Principal investigator 1 PFIZER INC. $136.00 08/05/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228842474
Principal investigator 1 Incyte Corporation $1,419.30 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589941
Principal investigator 1 ABBVIE INC. $296.31 07/31/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202500616
Principal investigator 1 ABBVIE INC. $139.67 07/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202500528
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 07/30/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187321
Principal investigator 1 ABBVIE INC. $3,126.18 07/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202500310
Principal investigator 1 ABBVIE INC. $229.50 07/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202500312
Principal investigator 1 ABBVIE INC. $1,959.60 07/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202500394
Principal investigator 1 Incyte Corporation $600.00 07/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589878
Principal investigator 1 Janssen Research & Development, LLC $419.00 07/28/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187146
Principal investigator 1 PFIZER INC. $1,050.72 07/25/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228844928
Principal investigator 1 ABBVIE INC. $6,491.00 07/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202499532
Principal investigator 1 ABBVIE INC. $1,089.00 07/23/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202499312
Principal investigator 1 Incyte Corporation $168.61 07/23/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589891
Principal investigator 1 Incyte Corporation $378.00 07/23/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589908
Principal investigator 1 Incyte Corporation $1,944.00 07/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240589827
Principal investigator 1 Incyte Corporation $5,877.00 07/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589842
Principal investigator 1 Incyte Corporation $1,694.10 07/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589953
Principal investigator 1 Incyte Corporation $2,265.00 07/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589957
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,090.80 07/18/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434455
Principal investigator 1 Incyte Corporation $1,731.60 07/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589834
Principal investigator 1 Incyte Corporation $464.00 07/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589982
Principal investigator 1 Incyte Corporation $189.00 07/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589831
Principal investigator 1 Incyte Corporation $1,482.50 07/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589839
Principal investigator 1 Incyte Corporation $83.40 07/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589846
Principal investigator 1 Incyte Corporation $417.00 07/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589849
Principal investigator 1 Incyte Corporation $590.75 07/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589854
Principal investigator 1 Incyte Corporation $1,631.90 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589914
Principal investigator 1 Incyte Corporation $1,271.56 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589919
Principal investigator 1 Incyte Corporation $294.00 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589924
Principal investigator 1 Incyte Corporation $2,237.00 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589928
Principal investigator 1 Incyte Corporation $132.00 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589932
Principal investigator 1 Incyte Corporation $58.00 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589935
Principal investigator 1 Incyte Corporation $84.00 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589997
Principal investigator 1 Incyte Corporation $109.56 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590006
Principal investigator 1 Incyte Corporation $1,577.00 07/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240590009
Principal investigator 1 ABBVIE INC. $70.00 07/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497394
Principal investigator 1 Janssen Research & Development, LLC $100.00 07/04/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187085
Principal investigator 1 ABBVIE INC. $2,633.40 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202494463
Principal investigator 1 ABBVIE INC. $2,106.00 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202494591
Principal investigator 1 ABBVIE INC. $3,015.72 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202494689
Principal investigator 1 ABBVIE INC. $28,527.93 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202494691
Principal investigator 1 ABBVIE INC. $1,716.15 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202494825
Principal investigator 1 ABBVIE INC. $4,910.10 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202496269
Principal investigator 1 ABBVIE INC. $824.00 07/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202493773
Principal investigator 1 ABBVIE INC. $784.00 07/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202493775
Principal investigator 1 ABBVIE INC. $350.00 07/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202493835
Principal investigator 1 Incyte Corporation $3.18 07/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589977
Principal investigator 1 Incyte Corporation $148.85 07/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589990
Principal investigator 1 Incyte Corporation $270.80 07/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589994
Principal investigator 1 ABBVIE INC. $704.00 06/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202493207
Principal investigator 1 PFIZER INC. $2,441.73 06/26/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228852358
Principal investigator 1 Incyte Corporation $597.40 06/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589514
Principal investigator 1 Incyte Corporation $2,134.00 06/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589517
Principal investigator 1 Incyte Corporation $1,498.00 06/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589733
Principal investigator 1 Incyte Corporation $1,498.00 06/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589738
Principal investigator 1 Incyte Corporation $1,388.00 06/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589791
Principal investigator 1 Janssen Research & Development, LLC $419.00 06/24/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187258
Principal investigator 1 Janssen Research & Development, LLC $2,428.00 06/24/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187348
Principal investigator 1 ABBVIE INC. $548.10 06/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202492145
Principal investigator 1 ABBVIE INC. $59.76 06/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202491725
Principal investigator 1 Novartis Pharmaceuticals Corporation $51,564.90 06/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190311107
Principal investigator 1 ABBVIE INC. $60.00 06/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202491103
Principal investigator 1 Incyte Corporation $1,844.10 06/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589373
Principal investigator 1 ABBVIE INC. $67.32 06/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202490699
Principal investigator 1 Incyte Corporation $1,419.30 06/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589531
Principal investigator 1 ABBVIE INC. $1,230.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202490351
Principal investigator 1 ABBVIE INC. $996.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202490391
Principal investigator 1 Incyte Corporation $88.00 06/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589527
Principal investigator 1 Incyte Corporation $736.32 06/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589535
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589540
Principal investigator 1 Incyte Corporation $90.00 06/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589793
Principal investigator 1 ABBVIE INC. $6,580.55 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202487727
Principal investigator 1 ABBVIE INC. $5,869.38 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202487729
Principal investigator 1 ABBVIE INC. $125.00 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202487791
Principal investigator 1 ABBVIE INC. $4,564.00 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487793
Principal investigator 1 ABBVIE INC. $2,556.60 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202487987
Principal investigator 1 ABBVIE INC. $1,978.50 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202487989
Principal investigator 1 Incyte Corporation $34.35 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589644
Principal investigator 1 Incyte Corporation $74.04 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589648
Principal investigator 1 Incyte Corporation $0.93 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589652
Principal investigator 1 Incyte Corporation $48.54 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589655
Principal investigator 1 Incyte Corporation $41.20 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589671
Principal investigator 1 Incyte Corporation $16.48 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589683
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589686
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589699
Principal investigator 1 Incyte Corporation $21.87 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589703
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589802
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589807
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 06/03/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434451
Principal investigator 1 ABBVIE INC. $127.32 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202486793
Principal investigator 1 ABBVIE INC. $379.50 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202486795
Principal investigator 1 ABBVIE INC. $72.33 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202486801
Principal investigator 1 ABBVIE INC. $156.83 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202486803
Principal investigator 1 ABBVIE INC. $556.14 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202486827
Principal investigator 1 ABBVIE INC. $9,291.00 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202486937
Principal investigator 1 ABBVIE INC. $784.00 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202486999
Principal investigator 1 ABBVIE INC. $273.24 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202487001
Principal investigator 1 ABBVIE INC. $506.90 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202487003
Principal investigator 1 ABBVIE INC. $704.00 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202487007
Principal investigator 1 ABBVIE INC. $224.40 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202487081
Principal investigator 1 ABBVIE INC. $43.56 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487083
Principal investigator 1 ABBVIE INC. $120.00 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202487085
Principal investigator 1 ABBVIE INC. $824.00 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202487095
Principal investigator 1 Incyte Corporation $11,754.00 05/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589369
Principal investigator 1 ABBVIE INC. $60.00 05/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202486153
Principal investigator 1 ABBVIE INC. $215.16 05/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202486159
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 05/27/2025 Non-covered Recipient Entity
Skin Care Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145062
Principal investigator 1 ABBVIE INC. $83.46 05/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202485755
Principal investigator 1 Incyte Corporation $470.70 05/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589348
Principal investigator 1 Incyte Corporation $1,388.00 05/21/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589442
Principal investigator 1 Incyte Corporation $1,388.00 05/21/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589446
Principal investigator 1 Incyte Corporation $1,070.60 05/21/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589452
Principal investigator 1 Eli Lilly and Company $1,200.00 05/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187889996
Principal investigator 1 Incyte Corporation $1,106.61 05/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589344
Principal investigator 1 Incyte Corporation $209.00 05/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589353
Principal investigator 1 Incyte Corporation $76.00 05/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589357
Principal investigator 1 Incyte Corporation $144.00 05/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589361
Principal investigator 1 Incyte Corporation $3,267.00 05/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589365
Principal investigator 1 ABBVIE INC. $440.00 05/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202484683
Principal investigator 1 ABBVIE INC. $1,078.44 05/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202484689
Principal investigator 1 Incyte Corporation $90.00 05/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589457
Principal investigator 1 Incyte Corporation $132.00 05/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589461
Principal investigator 1 Incyte Corporation $88.00 05/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589468
Principal investigator 1 Incyte Corporation $787.08 05/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589472
Principal investigator 1 Incyte Corporation $60.00 05/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589476
Principal investigator 1 Incyte Corporation $100.00 05/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589712
Principal investigator 1 ABBVIE INC. $784.00 05/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202484499
Principal investigator 1 ABBVIE INC. $43.56 05/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202484503
Principal investigator 1 ABBVIE INC. $118.80 05/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202484529
Principal investigator 1 ABBVIE INC. $32,923.78 05/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482433
Principal investigator 1 ABBVIE INC. $4,567.47 05/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202482571
Principal investigator 1 ABBVIE INC. $3,310.08 05/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483559
Principal investigator 1 ABBVIE INC. $10,726.22 05/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202484021
Principal investigator 1 Incyte Corporation $1,608.00 05/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589486
Principal investigator 1 Incyte Corporation $1,419.30 05/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589490
Principal investigator 1 ABBVIE INC. $27.82 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202481173
Principal investigator 1 ABBVIE INC. $111.28 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202481207
Principal investigator 1 ABBVIE INC. $3,466.00 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481289
Principal investigator 1 ABBVIE INC. $125.19 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202481957
Principal investigator 1 ABBVIE INC. $55.64 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202482239
Principal investigator 1 ABBVIE INC. $139.10 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482265
Principal investigator 1 ABBVIE INC. $1,576.40 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202482267
Principal investigator 1 PFIZER INC. $1,050.72 05/06/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228856166
Principal investigator 1 Janssen Research & Development, LLC $1,265.00 05/05/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187354
Principal investigator 1 Incyte Corporation $348.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589381
Principal investigator 1 Incyte Corporation $75.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589393
Principal investigator 1 Incyte Corporation $34.01 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589397
Principal investigator 1 Incyte Corporation $86.94 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589402
Principal investigator 1 Incyte Corporation $88.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589428
Principal investigator 1 Incyte Corporation $60.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589464
Principal investigator 1 Incyte Corporation $60.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589479
Principal investigator 1 Incyte Corporation $372.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589482
Principal investigator 1 Incyte Corporation $66.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589495
Principal investigator 1 Incyte Corporation $413.16 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589499
Principal investigator 1 Incyte Corporation $168.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589503
Principal investigator 1 Incyte Corporation $1,022.40 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589507
Principal investigator 1 Incyte Corporation $66.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589511
Principal investigator 1 Incyte Corporation $200.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589523
Principal investigator 1 Incyte Corporation $58.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589556
Principal investigator 1 Incyte Corporation $135.40 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589660
Principal investigator 1 Incyte Corporation $270.80 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589663
Principal investigator 1 Incyte Corporation $12.72 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589668
Principal investigator 1 Incyte Corporation $64.72 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589675
Principal investigator 1 Incyte Corporation $54.76 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589678
Principal investigator 1 Incyte Corporation $98.72 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589692
Principal investigator 1 Incyte Corporation $160.30 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589695
Principal investigator 1 Incyte Corporation $45.80 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589710
Principal investigator 1 Incyte Corporation $1,388.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589717
Principal investigator 1 Incyte Corporation $210.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589730
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589746
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589753
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589758
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589763
Principal investigator 1 Incyte Corporation $116.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589788
Principal investigator 1 Incyte Corporation $1,498.00 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589797
Principal investigator 1 Incyte Corporation $50.90 05/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589823
Principal investigator 1 ABBVIE INC. $153.01 05/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202480771
Principal investigator 1 ABBVIE INC. $55.64 05/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202480863
Principal investigator 1 ABBVIE INC. $282.48 04/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202480501
Principal investigator 1 ABBVIE INC. $824.00 04/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202480633
Principal investigator 1 ABBVIE INC. $1,345.50 04/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202480635
Principal investigator 1 ABBVIE INC. $178.20 04/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202479748
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 04/28/2025 Non-covered Recipient Entity
Skin Care Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145052
Principal investigator 1 SANOFI US SERVICES INC. $5,349.00 04/28/2025 Non-covered Recipient Entity
Skin Care Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145055
Principal investigator 1 ABBVIE INC. $55.95 04/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202478796
Principal investigator 1 ABBVIE INC. $158.20 04/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202478800
Principal investigator 1 ABBVIE INC. $704.00 04/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202478812
Principal investigator 1 ABBVIE INC. $120.00 04/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202478816
Principal investigator 1 ABBVIE INC. $58.91 04/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202478860
Principal investigator 1 Incyte Corporation $2,735.10 04/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240589377
Principal investigator 1 Janssen Research & Development, LLC $3,021.00 04/24/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187051
Principal investigator 1 Janssen Research & Development, LLC $134.00 04/24/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187130
Principal investigator 1 Janssen Research & Development, LLC $1,457.00 04/24/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187138
Principal investigator 1 Incyte Corporation $130.00 04/23/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589321
Principal investigator 1 ABBVIE INC. $241.80 04/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202478257
Principal investigator 1 Incyte Corporation $497.00 04/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589390
Principal investigator 1 Incyte Corporation $42.00 04/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589412
Principal investigator 1 Incyte Corporation $1,929.76 04/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589419
Principal investigator 1 Incyte Corporation $120.00 04/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589424
Principal investigator 1 ABBVIE INC. $704.00 04/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202477288
Principal investigator 1 ABBVIE INC. $784.00 04/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202477313
Principal investigator 1 ABBVIE INC. $824.00 04/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202477721
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,181.60 04/17/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434447
Principal investigator 1 ABBVIE INC. $1,341.80 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202476438
Principal investigator 1 ABBVIE INC. $432.40 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202476442
Principal investigator 1 ABBVIE INC. $110.98 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202476460
Principal investigator 1 Incyte Corporation $257.15 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589313
Principal investigator 1 Incyte Corporation $484.25 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589317
Principal investigator 1 Incyte Corporation $417.00 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589325
Principal investigator 1 Incyte Corporation $1,853.10 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589329
Principal investigator 1 Incyte Corporation $104.25 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589333
Principal investigator 1 Incyte Corporation $312.75 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589337
Principal investigator 1 ABBVIE INC. $55.64 04/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202475080
Principal investigator 1 ABBVIE INC. $6,648.00 04/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202474871
Principal investigator 1 Incyte Corporation $406.00 04/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589407
Principal investigator 1 Incyte Corporation $1,577.00 04/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589415
Principal investigator 1 Incyte Corporation $2,237.00 04/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589431
Principal investigator 1 Incyte Corporation $2,237.00 04/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589434
Principal investigator 1 Incyte Corporation $232.00 04/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589439
Principal investigator 1 Incyte Corporation $432.80 04/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589777
Principal investigator 1 Incyte Corporation $1,577.00 04/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589783
Principal investigator 1 Incyte Corporation $2,237.00 04/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589819
Principal investigator 1 ABBVIE INC. $1,408.00 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202468793
Principal investigator 1 ABBVIE INC. $553.40 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202469425
Principal investigator 1 ABBVIE INC. $1,230.60 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202469607
Principal investigator 1 ABBVIE INC. $6,351.00 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202469609
Principal investigator 1 ABBVIE INC. $24,826.54 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470448
Principal investigator 1 ABBVIE INC. $6,846.12 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202473751
Principal investigator 1 ABBVIE INC. $1,936.46 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202473942
Principal investigator 1 ABBVIE INC. $5,092.65 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202473946
Principal investigator 1 Incyte Corporation $116.00 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589386
Principal investigator 1 Incyte Corporation $372.00 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589450
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589544
Principal investigator 1 Incyte Corporation $190.80 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589548
Principal investigator 1 Incyte Corporation $180.20 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589552
Principal investigator 1 Incyte Corporation $64.72 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589561
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589565
Principal investigator 1 Incyte Corporation $24.72 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589569
Principal investigator 1 Incyte Corporation $9.72 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589574
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589579
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589583
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589588
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589594
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589598
Principal investigator 1 Incyte Corporation $37.66 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589603
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589607
Principal investigator 1 Incyte Corporation $42.40 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589612
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589616
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589620
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589624
Principal investigator 1 Incyte Corporation $201.40 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589627
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589631
Principal investigator 1 Incyte Corporation $42.40 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589635
Principal investigator 1 Incyte Corporation $58.30 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589640
Principal investigator 1 Incyte Corporation $106.00 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589706
Principal investigator 1 Incyte Corporation $270.80 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589720
Principal investigator 1 Incyte Corporation $169.60 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589725
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589741
Principal investigator 1 Incyte Corporation $1,388.00 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589767
Principal investigator 1 Incyte Corporation $1,073.20 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589770
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589811
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589815
Principal investigator 1 ABBVIE INC. $1,897.50 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202467749
Principal investigator 1 ABBVIE INC. $988.08 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202467753
Principal investigator 1 ABBVIE INC. $367.85 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202467767
Principal investigator 1 ABBVIE INC. $1,043.28 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202467973
Principal investigator 1 ABBVIE INC. $68.00 03/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202466177
Principal investigator 1 ABBVIE INC. $2,064.15 03/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202465728
Principal investigator 1 ABBVIE INC. $651.36 03/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202465743
Principal investigator 1 ABBVIE INC. $1,540.00 03/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202465808
Principal investigator 1 Incyte Corporation $1,965.60 03/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589027
Principal investigator 1 Incyte Corporation $3,000.00 03/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589039
Principal investigator 1 PFIZER INC. $2,101.44 03/22/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228861370
Principal investigator 1 Janssen Research & Development, LLC $100.00 03/20/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187070
Principal investigator 1 Janssen Research & Development, LLC $419.00 03/20/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187153
Principal investigator 1 Janssen Research & Development, LLC $1,850.00 03/20/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187329
Principal investigator 1 SANOFI US SERVICES INC. $4,077.62 03/17/2025 Non-covered Recipient Entity
Skin Care Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226144912
Principal investigator 1 SANOFI US SERVICES INC. $578.00 03/17/2025 Non-covered Recipient Entity
Skin Care Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226144944
Principal investigator 1 Incyte Corporation $120.00 03/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589045
Principal investigator 1 Janssen Research & Development, LLC $58.00 03/14/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187107
Principal investigator 1 Janssen Research & Development, LLC $58.00 03/14/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187340
Principal investigator 1 Janssen Research & Development, LLC $58.00 03/14/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187371
Principal investigator 1 PFIZER INC. $1,495.73 03/14/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228861362
Principal investigator 1 Incyte Corporation $1,608.00 03/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589144
Principal investigator 1 Incyte Corporation $702.10 03/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589148
Principal investigator 1 Incyte Corporation $1,577.00 03/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589152
Principal investigator 1 Incyte Corporation $1,577.00 03/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589157
Principal investigator 1 Incyte Corporation $2,237.00 03/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589170
Principal investigator 1 Incyte Corporation $1,577.00 03/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589288
Principal investigator 1 ABBVIE INC. $289.31 03/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462283
Principal investigator 1 ABBVIE INC. $7,556.25 03/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202459150
Principal investigator 1 ABBVIE INC. $10,544.06 03/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202459913
Principal investigator 1 ABBVIE INC. $3,287.64 03/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202460175
Principal investigator 1 ABBVIE INC. $639.15 03/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202460186
Principal investigator 1 ABBVIE INC. $13,973.66 03/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460193
Principal investigator 1 ABBVIE INC. $3,285.00 03/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202457217
Principal investigator 1 ABBVIE INC. $641.72 03/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202457554
Principal investigator 1 ABBVIE INC. $92.74 03/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202458636
Principal investigator 1 ABBVIE INC. $1,835.40 03/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202455799
Principal investigator 1 ABBVIE INC. $27.82 03/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202455816
Principal investigator 1 Incyte Corporation $500.00 03/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589032
Principal investigator 1 Incyte Corporation $1,200.00 03/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589035
Principal investigator 1 Incyte Corporation $195.00 03/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240589042
Principal investigator 1 Incyte Corporation $1,498.00 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589161
Principal investigator 1 Incyte Corporation $1,198.40 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589165
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589194
Principal investigator 1 Incyte Corporation $34.35 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589198
Principal investigator 1 Incyte Corporation $98.72 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589202
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589206
Principal investigator 1 Incyte Corporation $1.24 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589210
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589223
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589226
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589230
Principal investigator 1 Incyte Corporation $74.04 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589233
Principal investigator 1 Incyte Corporation $57.54 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589237
Principal investigator 1 Incyte Corporation $57.54 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589240
Principal investigator 1 Incyte Corporation $45.80 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589245
Principal investigator 1 Incyte Corporation $80.90 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589249
Principal investigator 1 Incyte Corporation $14.84 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589260
Principal investigator 1 Incyte Corporation $21.87 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589268
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589272
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589275
Principal investigator 1 Incyte Corporation $57.54 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589293
Principal investigator 1 Incyte Corporation $57.54 03/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589297
Principal investigator 1 ABBVIE INC. $139.10 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202454435
Principal investigator 1 ABBVIE INC. $363.15 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202454439
Principal investigator 1 ABBVIE INC. $32.46 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202454446
Principal investigator 1 ABBVIE INC. $150.23 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202454449
Principal investigator 1 ABBVIE INC. $784.00 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202454452
Principal investigator 1 ABBVIE INC. $306.95 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202454456
Principal investigator 1 ABBVIE INC. $824.00 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202454677
Principal investigator 1 ABBVIE INC. $225.72 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202454681
Principal investigator 1 ABBVIE INC. $5,802.00 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202454684
Principal investigator 1 ABBVIE INC. $268.93 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202454688
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.00 02/27/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434443
Principal investigator 1 ABBVIE INC. $175.01 02/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202454048
Principal investigator 1 ABBVIE INC. $122.84 02/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202454113
Principal investigator 1 ABBVIE INC. $59.91 02/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202454117
Principal investigator 1 ABBVIE INC. $1,408.00 02/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202454121
Principal investigator 1 ABBVIE INC. $350.00 02/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202453857
Principal investigator 1 Eli Lilly and Company $3,984.16 02/25/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187889992
Principal investigator 1 Incyte Corporation $100.00 02/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589048
Principal investigator 1 Incyte Corporation $42.00 02/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589117
Principal investigator 1 Incyte Corporation $158.00 02/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589121
Principal investigator 1 Incyte Corporation $1,003.32 02/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589130
Principal investigator 1 Incyte Corporation $4,714.24 02/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589133
Principal investigator 1 Incyte Corporation $58.00 02/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589187
Principal investigator 1 Incyte Corporation $294.00 02/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589283
Principal investigator 1 SANOFI US SERVICES INC. $1,421.00 02/24/2025 Non-covered Recipient Entity
Skin Care Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226144932
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 02/24/2025 Non-covered Recipient Entity
Skin Care Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226144948
Principal investigator 1 ABBVIE INC. $1,104.60 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202453069
Principal investigator 1 ABBVIE INC. $1,073.60 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202453210
Principal investigator 1 ABBVIE INC. $395.40 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202453214
Principal investigator 1 ABBVIE INC. $824.00 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202453251
Principal investigator 1 ABBVIE INC. $3,300.00 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202453255
Principal investigator 1 Incyte Corporation $1,733.00 02/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589113
Principal investigator 1 Incyte Corporation $2,237.00 02/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589125
Principal investigator 1 Incyte Corporation $706.90 02/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589140
Principal investigator 1 Incyte Corporation $1,577.00 02/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589305
Principal investigator 1 Incyte Corporation $1,577.00 02/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589309
Principal investigator 1 ABBVIE INC. $572.70 02/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202452306
Principal investigator 1 ABBVIE INC. $852.84 02/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202452377
Principal investigator 1 ABBVIE INC. $127.87 02/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202452395
Principal investigator 1 SANOFI US SERVICES INC. $55.64 02/18/2025 Non-covered Recipient Entity
Skin Care Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226144908
Principal investigator 1 Janssen Research & Development, LLC $58.00 02/14/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187289
Principal investigator 1 ABBVIE INC. $784.00 02/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202451288
Principal investigator 1 Incyte Corporation $1,853.10 02/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590269
Principal investigator 1 SANOFI US SERVICES INC. $1,600.00 02/10/2025 Non-covered Recipient Entity
Skin Care Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226144989
Principal investigator 1 SANOFI US SERVICES INC. $900.00 02/10/2025 Non-covered Recipient Entity
Skin Care Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226144991
Principal investigator 1 Incyte Corporation $84.00 02/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589137
Principal investigator 1 Incyte Corporation $66.00 02/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589263
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,181.60 02/07/2025 Non-covered Recipient Entity
Skin Care Research, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434439
Principal investigator 1 ABBVIE INC. $8,764.62 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202448525
Principal investigator 1 ABBVIE INC. $18,842.79 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202448529
Principal investigator 1 ABBVIE INC. $11,475.72 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202449728
Principal investigator 1 ABBVIE INC. $5,074.20 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202449766
Principal investigator 1 ABBVIE INC. $4,729.20 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202449788
Principal investigator 1 ABBVIE INC. $1,413.66 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202449795
Principal investigator 1 ABBVIE INC. $9,148.00 02/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202446215
Principal investigator 1 ABBVIE INC. $3,400.00 02/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202443792
Principal investigator 1 ABBVIE INC. $483.12 02/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202443603
Principal investigator 1 ABBVIE INC. $453.60 02/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202443609
Principal investigator 1 PFIZER INC. $1,128.60 02/03/2025 Non-covered Recipient Entity
Skin Care Research
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228715227
Principal investigator 1 ABBVIE INC. $214.65 01/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202443154
Principal investigator 1 ABBVIE INC. $293.04 01/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202441595
Principal investigator 1 ABBVIE INC. $1,501.92 01/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202441599
Principal investigator 1 Incyte Corporation $1,388.00 01/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589082
Principal investigator 1 Incyte Corporation $372.00 01/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589090
Principal investigator 1 Incyte Corporation $1,557.60 01/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589094
Principal investigator 1 Incyte Corporation $1,498.00 01/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589097
Principal investigator 1 Incyte Corporation $372.00 01/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589279
Principal investigator 1 PFIZER INC. $1,760.13 01/24/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228860577
Principal investigator 1 SANOFI US SERVICES INC. $1,950.00 01/24/2025 Non-covered Recipient Entity
Skin Care Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226144923
Principal investigator 1 Incyte Corporation $1,853.10 01/21/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590249
Principal investigator 1 Eli Lilly and Company $10,258.13 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187889994
Principal investigator 1 Incyte Corporation $159.70 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589056
Principal investigator 1 Incyte Corporation $1,577.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589060
Principal investigator 1 Incyte Corporation $1,577.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589073
Principal investigator 1 Incyte Corporation $1,577.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589077
Principal investigator 1 Incyte Corporation $2,237.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589086
Principal investigator 1 Incyte Corporation $1,577.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589101
Principal investigator 1 Incyte Corporation $1,577.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589104
Principal investigator 1 Incyte Corporation $1,577.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589107
Principal investigator 1 Incyte Corporation $1,707.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589257
Principal investigator 1 Incyte Corporation $1,247.40 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590254
Principal investigator 1 Incyte Corporation $502.00 01/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590263
Principal investigator 1 Janssen Research & Development, LLC $6,122.00 01/16/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187057
Principal investigator 1 Incyte Corporation $1,388.00 01/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589063
Principal investigator 1 Incyte Corporation $300.00 01/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589067
Principal investigator 1 Incyte Corporation $1,061.20 01/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589218
Principal investigator 1 PFIZER INC. $418.50 01/15/2025 Non-covered Recipient Entity
Skin Care Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228860590
Principal investigator 1 ABBVIE INC. $824.00 01/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202438389
Principal investigator 1 ABBVIE INC. $106.88 01/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202438130
Principal investigator 1 ABBVIE INC. $704.00 01/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202438135
Principal investigator 1 ABBVIE INC. $2,800.00 01/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202437946
Principal investigator 1 Incyte Corporation $68.73 01/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589053
Principal investigator 1 Incyte Corporation $2,500.00 01/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589213
Principal investigator 1 Incyte Corporation $2,662.20 01/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240590259
Principal investigator 1 ABBVIE INC. $2,066.85 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202434747
Principal investigator 1 ABBVIE INC. $1,376.00 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202434751
Principal investigator 1 ABBVIE INC. $553.40 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202434779
Principal investigator 1 ABBVIE INC. $1,568.00 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202434906
Principal investigator 1 ABBVIE INC. $704.00 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202436065
Principal investigator 1 ABBVIE INC. $996.00 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202436069
Principal investigator 1 ABBVIE INC. $180.84 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202436138
Principal investigator 1 Incyte Corporation $206.10 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589174
Principal investigator 1 Incyte Corporation $135.40 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589177
Principal investigator 1 Incyte Corporation $16.18 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589183
Principal investigator 1 Incyte Corporation $270.80 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589190
Principal investigator 1 Incyte Corporation $2.43 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589253
Principal investigator 1 Incyte Corporation $54.76 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240589301